SODIUM CHLORIDE SOLUTION 0.9%
Sponsors
Moderna Inc., Centre Hospitalier Universitaire De Nice, Daiichi Sankyo Inc., Eli Lilly & Co., Janssen - Cilag International
Conditions
-Peripheral neuropathy clinically defined:
*Pure sensitive (lymph node disease) or sensorimotor neuropathies
*Proved EMG-Primary Sjögren's syndrome defined as per the European and American
criteriaAcute Ischemic StrokeAcute LeukemiaAcute Myeloblastic LeukemiaAcute lower respiratory infectionAtopic dermatitisBreast Cancer Female
Phase 1
A Phase 1b/2, Double-Blind, Placebo-Controlled, Randomized, Parallel-Arm Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients with Netherton Syndrome
CompletedCTIS2022-502853-32-00
Start: 2023-08-18End: 2025-01-06Target: 12Updated: 2024-10-15
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 months to < 24 months
CompletedCTIS2022-502022-41-00
Start: 2024-05-28End: 2024-12-18Target: 248Updated: 2024-09-24
A Phase 1/2, Global, Open-Label, Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705.
RecruitingCTIS2022-501997-20-00
Start: 2023-12-01Target: 26Updated: 2025-12-12
A Phase 1b/2a Open-Label Dose-Finding Followed by Randomized, Double-Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of TGD001 in Patients with Acute Ischemic Stroke
RecruitingCTIS2025-522455-26-00
Start: 2025-12-17Target: 80Updated: 2026-01-20
Phase 2
Study With Temsirolimus Added to Standard Chemotherapy for Patients Over 60 Years With Acute Myeloblastic Leukemia
CompletedNCT01611116
Start: 2012-05-31End: 2017-04-26Updated: 2023-05-24
J4E-MC-IMMB: A Master Protocol for Randomized, Controlled, Phase 2 Clinical Trials of Multiple Interventions for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis;
J4E-MC-FR01: A Phase 2, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of LY3454738 in the Treatment of Adult Patients with Moderate-to-Severe Atopic Dermatitis
CompletedCTIS2022-502888-38-00
Start: 2023-09-25End: 2024-12-11Target: 94Updated: 2024-12-11
A Phase 2, Multicenter, Randomized, Double-blind, Placebo‑controlled Study with Deferred Active Treatment to Investigate the Efficacy, Safety, and Pharmacokinetics of JNJ‑73763989 + Nucleos(t)ide Analog in Participants Co‑infected with Hepatitis B and Hepatitis D Virus
CompletedCTIS2023-506763-33-00
Start: 2020-12-18End: 2025-01-15Target: 14Updated: 2024-09-02
A Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Reactogenicity, Safety, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Pregnant Women, and Safety, and Immunogenicity in Infants Born to Vaccinated Mothers.
CompletedCTIS2023-505359-37-00
Start: 2024-09-03End: 2025-04-30Target: 25Updated: 2025-02-20
Randomised double-blind clinical trial of Onabotulinumtoxin A injection into the corpora cavernosa in patients with erectile dysfunction refractory to treatment with phosphodiesterase-5 inhibitors
RecruitingCTIS2024-514518-10-00
Start: 2024-10-31Target: 114Updated: 2025-12-29
Methotrexate treatment in hand osteoarthritis refractory to usual treatments: A randomised, double-blind, placebo-controlled trial, ADEM2 study
Not yet recruitingCTIS2022-502362-24-00
Target: 170Updated: 2025-10-17
Phase 3
Use of GnRHa During Chemotherapy for Fertility Protection
RecruitingNCT05328258
Start: 2023-03-31End: 2032-01-31Target: 500Updated: 2023-10-27
Prospective, randomised, placebo-controlled study of polyvalent intravenous immunoglobulins for the treatment of primary Sjögren's syndrome associated painful sensory neuropathies
CompletedCTIS2024-517309-95-00
Start: 2019-06-19End: 2025-04-10Target: 24Updated: 2024-10-08
Evaluation of the efficacy of treatment with mucosal bacterial vaccines(autovaccines) versus suppressive antibiotic treatment in subjects with hip or knee prosthesis infections.
Not yet recruitingCTIS2024-520226-10-00
Target: 20Updated: 2025-01-23
Immediate post-surgical Botulinum toxin injections to prevent dystrophic Scars after sternotomy : a placebo-controlled randomized clinical trial - BotuCiSter
Not yet recruitingCTIS2025-521290-14-00
Target: 50Updated: 2025-08-06